instruments must be requested in writing.

Proposed Collection: NIH Office of Intramural Training & Education Application, 0925–0299 Revision, Office of the Director (OD), National Institutes of Health (NIH).

Need and Use of Information Collection: The Office of Intramural Training & Education (OITE) administers a variety of programs and initiatives to recruit pre-college through post-doctoral educational level individuals into the National Institutes of Health Intramural Research Program (NIH–IRP) to facilitate develop into future biomedical scientists. The proposed information collection is necessary in order to determine the eligibility and quality of potential awardees for traineeships in these programs. The applications for admission consideration include key areas such as: Personal information, eligibility criteria, contact information, student identification number, training program selection, scientific discipline interests, educational history, standardized examination scores, reference information, resume components, employment history, employment interests, dissertation research details, letters of recommendation, financial aid history, sensitive data, future networking contact, travel information, as well as feedback questions about interviews and application submission experiences. Sensitive data collected on the applicants, race, gender, ethnicity, disability, and recruitment method, are made available only to OITE staff members or in aggregate form to select NIH offices and are not used by the admission committee for admission consideration; optional to submit.

OMB approval is requested for 3 years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 18,354.00.

ESTIMATED ANNUALIZED BURDEN HOURS

<table>
<thead>
<tr>
<th>Type of respondent</th>
<th>Estimated number of respondents</th>
<th>Estimated number of responses annually per respondent</th>
<th>Estimated total annual burden hours</th>
<th>Estimated total annual burden hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Summer Internship Program in Biomedical Research (SIP)</td>
<td>6,820.0</td>
<td>1.0</td>
<td>1.0</td>
<td>6,820.00</td>
</tr>
<tr>
<td>Biomedical Engineering Summer Internship Program (BESIP)</td>
<td>80.0</td>
<td>1.0</td>
<td>1.0</td>
<td>80.00</td>
</tr>
<tr>
<td>Post-baccalaureate Training Program (PBT)</td>
<td>1,885.0</td>
<td>1.0</td>
<td>1.0</td>
<td>1,885.00</td>
</tr>
<tr>
<td>Community College Summer Enrichment Program (CCSEP)</td>
<td>100.0</td>
<td>1.0</td>
<td>1.0</td>
<td>100.00</td>
</tr>
<tr>
<td>Technical Training Program (PTT)</td>
<td>115.0</td>
<td>1.0</td>
<td>1.0</td>
<td>115.00</td>
</tr>
<tr>
<td>Graduate Partnerships Program (GPP)—Application (Select Institutional Partnerships)</td>
<td>250.0</td>
<td>1.0</td>
<td>1.0</td>
<td>250.00</td>
</tr>
<tr>
<td>Graduate Partnerships Program (GPP)—Registration (Select Institutional Partnerships + Individual Partnership)</td>
<td>140.0</td>
<td>1.0</td>
<td>1.0</td>
<td>140.00</td>
</tr>
<tr>
<td>National Graduate Student Research Conference (NGSRC)</td>
<td>800.0</td>
<td>1.0</td>
<td>1.0</td>
<td>800.00</td>
</tr>
<tr>
<td>Undergraduate Scholarship Program (UGSP)</td>
<td>200.0</td>
<td>1.0</td>
<td>1.0</td>
<td>200.00</td>
</tr>
<tr>
<td>Alumni Database</td>
<td>1,900.0</td>
<td>1.0</td>
<td>1.0</td>
<td>1,900.00</td>
</tr>
<tr>
<td>UGSP—Certificate of Eligibility (Completed by Applicant)</td>
<td>200.0</td>
<td>1.0</td>
<td>3/60</td>
<td>10.00</td>
</tr>
<tr>
<td>UGSP—Certificate of Eligibility (Completed by University Staff)</td>
<td>200.0</td>
<td>1.0</td>
<td>15/60</td>
<td>50.00</td>
</tr>
<tr>
<td>UGSP—Deferral Form (Completed by Applicant)</td>
<td>40.0</td>
<td>1.0</td>
<td>3/60</td>
<td>2.00</td>
</tr>
<tr>
<td>UGSP—Deferral Form (Completed by University Staff)</td>
<td>40.0</td>
<td>1.0</td>
<td>15/60</td>
<td>10.00</td>
</tr>
<tr>
<td>Reference Recommendation Letters for All Programs</td>
<td>23,235.0</td>
<td>1.0</td>
<td>15/60</td>
<td>5,808.75</td>
</tr>
<tr>
<td>Survey—Race-Ethnicity-Gender-Birth Year (25% Response Rate)</td>
<td>3,073.0</td>
<td>1.0</td>
<td>3/60</td>
<td>153.65</td>
</tr>
<tr>
<td>Survey—Time to Complete Application Form (4% Response Rate)</td>
<td>492.0</td>
<td>1.0</td>
<td>3/60</td>
<td>24.60</td>
</tr>
<tr>
<td>Survey—GPP Interview Experience (60% Response Rate)</td>
<td>30.0</td>
<td>1.0</td>
<td>10/60</td>
<td>5.00</td>
</tr>
<tr>
<td>Totals</td>
<td>39,600.0</td>
<td>N/A</td>
<td>N/A</td>
<td>18,354.00</td>
</tr>
</tbody>
</table>

Dated: July 1, 2013.

Richard Wyatt, Executive Director, Office of Intramural Research, OD, National Institutes of Health.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Cancer Institute Special Emphasis Panel, July 30, 2013, 9:00 a.m.–4:00 p.m., National Cancer Institute, 9609 Medical Center Drive, Room 2W908 Rockville, MD, 20850 which was published in the Federal Register on June 17, 2013, 78FR36201.

This notice is being amended to change the meeting format from a face to face meeting to a teleconference. Also the meeting date and time are now 10:30 a.m. to 12:00 p.m. on August 12, 2013. The meeting is closed to the public.

Dated: July 9, 2013.

David Clary, Program Analyst, Office of Federal Advisory Committee Policy.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Agency Information Collection Activities: Submission for Office of Management and Budget (OMB) Review; Comment Request

Periodically, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish a summary of information collection requests under OMB review, in compliance with the Government Paperwork Elimination Act (GPEA) 44 U.S.C. 3504. To request a copy of these documents, call the SAMHSA Reports Clearance Office at (240) 276–1243.
Project: Mandatory Guidelines for Federal Workplace Drug Testing Programs (OMB No. 0930–0158)—Revision

SAMHSA will request OMB approval for the Federal Drug Testing Custody and Control Form (Federal CCF) for federal agency and federally regulated drug testing programs which must comply with the HHS Mandatory Guidelines for Federal Workplace Drug Testing Programs (73 FR 71858) dated November 25, 2008, and OMB approval for the information provided by test facilities (i.e., laboratories and Instrumented Initial Test Facilities, IITFs) for the National Laboratory Certification Program (NLCP).

The Federal CCF is used by all federal agencies and employers regulated by the Department of Transportation (DOT) to document the collection and chain of custody of drug testing specimens at the collection site, for the test facility to report results, and for the Medical Review Officer (MRO) to make a determination. The current OMB-approved Federal CCF has an August 31, 2013 expiration date. In accordance with the GPEA, OMB set terms of clearance for the extension of the current Federal CCF as follows: Prior to the next approval of this package, the Agency (SAMHSA) shall provide a progress update on adoption of electronic forms in an effort to reduce burden. SAMHSA is encouraged to explore ways to convert the Federal Drug Testing Custody and Control Form (Federal CCF) into an electronic form.

In an effort to comply with the stated terms of the clearance requirement set forth by OMB, SAMHSA will authorize the use of an electronic Federal CCF. SAMHSA has resubmitted the Federal CCF with no content revisions to the form for OMB approval. The only revisions are to enable the form to be used as a paper form or as an electronic form.

• The first change to the Federal CCF is to allow the Public Burden Statement to be a separate page of an electronic Federal CCF. The Public Burden Statement must appear on all federal government forms that place a reporting burden on gathering information.

• The second change is to allow the Federal CCF instructions and the Privacy Act Statement to be on a separate page or pages of an electronic Federal CCF.

• The third change is to allow the bottle labels/seals to be printed separately, and not as a part of Copy 1 of the Federal CCF.

• The fourth change is to revise the Federal CCF Instructions to allow the use of an electronic form.

Below is a copy of the Federal CCF:
FEDERAL DRUG TESTING CUSTODY AND CONTROL FORM

SPECIMEN ID NO. 0000001

A. Employer Name, Address, I.D. No.  
B. MRO Name, Address, Phone No. and Fax No.

C. Donor SSN or Employee I.D. No.  

D. Specify Testing Authority:  
   - HHS  
   - NRC  
   - DOT – Specify DOT Agency:  
     - FMCSA  
     - FAA  
     - FRA  
     - FTA  
     - PHMSA  
     - USCG  

E. Reason for Test:  
   - Pre-employment  
   - Random  
   - Reasonable Suspicion/Cause  
   - Post Accident  
   - Return to Duty  
   - Follow-up  
   - Other (specify)  

F. Drug Tests to be Performed:  
   - THC, COC, PCP, OPI, AMP  
   - THC & COC Only  
   - Other (specify)  

G. Collection Site Address:  
   
   Collector Phone No.  
   Collector Fax No.  

Step 2: Completed by Collector (make remarks when appropriate) Collector reads specimen temperature within 4 minutes.  

- Temperature between 90° and 100°F?  
  - Yes  
  - No  
  - Enter Remark  

Collector:  
   - Split  
   - Single  
   - None Provided, Enter Remark  
   - Observed, Enter Remark  

Remarks  

Step 3: Collector affixes bottle seal(s) to bottle(s). Collector dates seal(s). Donor initiates seal(s). Donor completes Step 5 on Copy 2 (MRO Copy)  

REMINDS  

Step 4: Chain of Custody - Initiated by Collector and Completed by Test Facility  

I certify that the specimen given to me by the donor identified in the certification section on Copy 2 of this form was collected, labeled, sealed and released to the Delivery Service noted in accordance with applicable Federal requirements.

Signature of Collector  

(AM PM)  

RECEIVED AT ITTF:  

Signature of Accessor  

Primary Specimen Bottle Seal Intact:  
   - Yes  
   - No  

If NO, Enter remark in Step 5A.

TRANSFER FROM ITTF TO LAB. I certify that the specimen identified on this form was handled using chain of custody procedures and released in accordance with applicable Federal requirements.

Signature of Accessor

(AM PM)  

RECEIVED AT LAB:  

Signature of Accessor

(AM PM)  

Step 5A: Primary Specimen Report - Completed by Test Facility  

- NEGATIVE  
- DILUTE  
- POSITIVE for:  
  - Marijuana Metabolite (DOC-THCA)  
  - 6-Acetyl morphine  
  - Methamphetamine  
  - MDMA  
  - Cocaine Metabolite (BZE)  
  - Morphine  
  - Amphetamine  
  - MDA  
  - PCP  
  - Codeine  
  - MDEA  

- REJECTED FOR TESTING  
- ADULTERATED  
- SUBSTITUTED  
- INVALID RESULT  

Remarks  

Test Facility (if different from above):  

I certify that the specimen identified on this form was examined upon receipt, handled using chain of custody procedures, analyzed, and reported in accordance with applicable Federal requirements.

Signature of Certifying Technician/Scientist

(AM PM)  

Step 5B: Completed by Split Testing Laboratory  

Split Testing Laboratory Name, City, State

Signature of Certifying Technician/Scientist

(AM PM)  

Paper CCF: Back of Copy 1–4  
Electronic CCF: Separate Page  

Public Burden Statement  

Public Burden Statement: An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. The OMB control number for this project is 0930–0158. Public reporting burden for this collection of information is estimated to average: 5 minutes/donor; 4 minutes/collector; 3 minutes/test facility; and 3 minutes/Medical Review Officer. Send comments regarding this burden estimate or any other aspect of this...
FEDERAL DRUG TESTING CUSTODY AND CONTROL FORM

SPECIMEN ID NO. 0000001

STEP 1: COMPLETED BY COLLECTOR OR EMPLOYER REPRESENTATIVE

A. Employer Name, Address, I.D. No. B. MRO Name, Address, Phone No. and Fax No.

C. Donor SSN or Employee I.D. No.

D. Specify Testing Authority: [ ] HHS [ ] NRC [ ] DOT – Specify DOT Agency: [ ] PMCSA [ ] FAA [ ] FRA [ ] FTA [ ] PHMSA [ ] USC

E. Reason for Test: [ ] Pre-employment [ ] Random [ ] Reasonable Suspicion Cause [ ] Post Accident [ ] Return to Duty [ ] Follow-up [ ] Other (Specify)

F. Drug Tests to be Performed: [ ] THC [ ] COC [ ] PCE [ ] OPI [ ] AMP [ ] THC & COC Only [ ] Other (Specify)

G. Collection Site Address:

Collector Phone No.

Collector Fax No.

STEP 2: COMPLETED BY COLLECTOR (make remarks when appropriate) Collector reads specimen temperature within 4 minutes.

Temperature between 80° and 100°F [ ] Yes [ ] No, Enter Remark

Collection: [ ] Split [ ] Single [ ] None Provided, Enter Remark [ ] Observed, Enter Remark

REMARKS:

STEP 3: Collector affixes bottle seal(s) to bottle(s). Collector dates seal(s), Donor initiates seal(s), Donor completes STEP 5 on Copy 2 (MRO Copy)

STEP 4: CHAIN OF CUSTODY - INITIATED BY COLLECTOR AND COMPLETED BY TEST FACILITY

I certify that the specimen given to me by the donor identified in the verification section on Copy 2 of this form was collected, labeled, sealed and released to the Delivery Service noted in accordance with applicable Federal requirements.

X Signature of Collector

AM [ ] PM

(PRINT) Collector's Name (First, M., Last) Date (MoDayYear) Time of Collection

STEP 6: COMPLETED BY DONOR

X Signature of Donor

Daytime Phone No. ( ) Evening Phone No. ( ) Date of Birth (MoDayYear)

After the Medical Review Officer receives the test results for the specimen identified by this form, he/she may contact you to ask about prescriptions and over-the-counter medications you may have taken. Therefore, you may want to make a list of those medications for your own records. THIS LIST IS NOT NECESSARY. If you choose to make a list, do so either on a separate piece of paper or on the back of your copy (Copy 5). DO NOT PROVIDE THIS INFORMATION ON THE BACK OF ANY OTHER COPY OF THE FORM. TAKE COPY 6 WITH YOU.

STEP 6: COMPLETED BY MEDICAL REVIEW OFFICER - PRIMARY SPECIMEN

In accordance with applicable Federal requirements, my verification is:

[ ] NEGATIVE [ ] POSITIVE for:

[ ] DILUTE

[ ] REFUSAL TO TEST because – check reason(s) below:

[ ] ADULTERATED (adult/urea/reason): [ ] TEST CANCELLED

[ ] SUBSTITUTED [ ] OTHER:

REMARKS:

X Signature of Medical Review Officer

(PRINT) Medical Review Officer’s Name (First, M., Last) Date (MoDayYear)

STEP 7: COMPLETED BY MEDICAL REVIEW OFFICER - SPLIT SPECIMEN

In accordance with applicable Federal requirements, my verification for the split specimen (if tested) is:

[ ] RECONFIRMED for: [ ] TEST CANCELLED

[ ] FAILED TO RECONFIRM for:

REMARKS:

X Signature of Medical Review Officer

(PRINT) Medical Review Officer’s Name (First, M., Last) Date (MoDayYear)
FEDERAL DRUG TESTING CUSTODY AND CONTROL FORM

<table>
<thead>
<tr>
<th>SPECIMEN ID NO.</th>
<th>0000001</th>
</tr>
</thead>
</table>

**STEP 1: COMPLETED BY COLLECTOR OR EMPLOYER REPRESENTATIVE**

<table>
<thead>
<tr>
<th>A. Employer Name, Address, I.D. No.</th>
<th>B. MRO Name, Address, Phone No. and Fax No.</th>
</tr>
</thead>
</table>

C. Donor SSN or Employee I.D. No.  

D. Specify Testing Authority: □ HHS □ NRC □ DOT – Specify DOT Agency: □ FMCSA □ FAA □ FRA □ FTA □ PHMSA □ USCG  

E. Reason for Test: □ Pre-employment □ Random □ Reasonable Suspicion/Cause □ Post Accident □ Return to Duty □ Follow-up □ Other (specify)  

F. Drug Tests to be Performed: □ THC □ COC □ PCR □ OPI □ AMP □ THC & COC Only □ Other (specify)  

G. Collection Site Address:  

Collector Phone No.  

Collector Fax No.  

**STEP 2: COMPLETED BY COLLECTOR (make remarks when appropriate) Collector reads specimen temperature within 4 minutes.**

Temperature between 90° and 100°F? □ Yes □ No, Enter Remark  

Collection: □ Split □ Single □ None Provided, Enter Remark □ Observed, Enter Remark  

**REMARKS:**

**STEP 3: Collector affixes bottle seal(s) to bottle(s). Collector dates seal(s). Donor initials seal(s). Donor completes STEP 5 on Copy 2 (MRO Copy)**

**STEP 4: CHAIN OF CUSTODY - INITIATED BY COLLECTOR AND COMPLETED BY TEST FACILITY**

I certify that the specimen given to me by the donor identified in the certification section on Copy 2 of this form was collected, labeled, sealed and released to the Delivery Service noted in accordance with applicable Federal requirements.

**SPECIMEN BOTTLE(S) RELEASED TO:**

**STEP 5: COMPLETED BY DONOR**

I certify that I provided my urine specimen to the collector; that I have not adulterated it in any manner; each specimen bottle used was sealed with a tamper-evident seal in my presence; and that the information provided on this form and on the label affixed to each specimen bottle is correct.

Signature of Donor  

Daytime Phone No. ( )  

Evening Phone No. ( )  

Date of Birth (Mc/Day/Yr)  

Date (Mc/Day/Yr)  

**STEP 6: COMPLETED BY MEDICAL REVIEW OFFICER - PRIMARY SPECIMEN**

In accordance with applicable Federal requirements, my verification is:

□ NEGATIVE □ POSITIVE for: □ DILUTE □ REFUSAL TO TEST because – check reason(s) below: □ ADULTERATED (adulterant/reason): □ SUBSTITUTED □ OTHER: □ TEST CANCELLED

**REMARKS:**

Signature of Medical Review Officer  

Date (Mc/Day/Yr)  

**STEP 7: COMPLETED BY MEDICAL REVIEW OFFICER - SPLIT SPECIMEN**

In accordance with applicable Federal requirements, my verification for the split specimen (if tested) is:

□ RECONFIRMED for: □ FAILED TO RECONFIRM for: □ TEST CANCELLED  

**REMARKS:**

Signature of Medical Review Officer  

Date (Mc/Day/Yr)  

COPY 3 - COLLECTOR COPY
FEDERAL DRUG TESTING CUSTODY AND CONTROL FORM

SPECIMEN ID NO. 0000001

STEP 1: COMPLETED BY COLLECTOR OR EMPLOYER REPRESENTATIVE

A. Employer Name, Address, I.D. No. B. MRO Name, Address, Phone No. and Fax No.

C. Donor SSN or Employee I.D. No. ________

D. Specify Testing Authority: ☐ HHS ☐ NRC ☐ DOT – Specify DOT Agency: ☐ FMCSA ☐ FAA ☐ FRA ☐ FTA ☐ PHMSA ☐ USCG

E. Reason for Test: ☐ Pre-employment ☐ Random ☐ Reasonable Suspicion/Cause ☐ Post Accident ☐ Return to Duty ☐ Follow-up ☐ Other (specify) ____________

F. Drug Tests to be Performed: ☐ THC, COC, PCP, OPI, AMP ☐ THC & COC Only ☐ Other (specify) ____________

G. Collection Site Address: ____________________________

Collector Phone No. ____________________________

Collector Fax No. ____________________________

STEP 2: COMPLETED BY COLLECTOR (make remarks when appropriate) Collector reads specimen temperature within 4 minutes.

Temperature between 90° and 100°F ☐ Yes ☐ No, Enter Remark Collection: ☐ Split ☐ Single ☐ None Provided, Enter Remark ☐ Observed, Enter Remark

REMARKS:

STEP 3: COLLECTOR offlines bottle seal(s) to bottle(s), Collector dates seal(s), Donor initials seal(s), Donor completes STEP 5 on Copy 2 (MRO Copy)

SPECIMEN BOTTLE(S) RELEASED TO: ____________________________

STEP 4: CHAIN OF CUSTODY - INITIATED BY COLLECTOR AND COMPLETED BY TEST FACILITY

I certify that the specimen given to me by the donor identified in the certification section on Copy 2 of this form was collected, labeled, sealed and released to the Delivery Service noted in accordance with applicable Federal requirements.

X__________________________________________

Signature of Collector AM PM ____________________________

(PRINT) Collector’s Name (First, M, Last) ____________________________

Date (Mo/Day/Yr) Time of Collection ____________________________

Name of Delivery Service ____________________________

STEP 5: COMPLETED BY DONOR

I certify that I provided my urine specimen to the collector; that I have not adulterated it in any manner; each specimen bottle used was sealed with a tamper-evident seal in my presence; and that the information provided on this form and on the label affixed to each specimen bottle is correct.

X__________________________________________

Signature of Donor ____________________________

(PRINT) Donor’s Name (First, M, Last) ____________________________

Daytime Phone No. (___) ____________________________

Evening Phone No. (___) ____________________________

Date of Birth (Mo/Day/Yr) ____________________________

After the Medical Review Officer receives the test results for the specimen identified by this form, he/she may contact you to ask about prescriptions and over-the-counter medications you may have taken. Therefore, you may want to make a list of those medications for your own records. THIS LIST IS NOT NECESSARY. If you choose to make a list, do so either on a separate piece of paper or on the back of your copy (Copy 5). – DO NOT PROVIDE THIS INFORMATION ON THE BACK OF ANY OTHER COPY OF THIS FORM. TAKE COPY 5 WITH YOU.

REMARKS:

X__________________________________________

Signature of Medical Review Officer ____________________________

(PRINT) Medical Review Officer’s Name (First, M, Last) ____________________________

Date (Mo/Day/Yr) ____________________________

STEP 6: COMPLETED BY MEDICAL REVIEW OFFICER - PRIMARY SPECIMEN

In accordance with applicable Federal requirements, my verification is:

☐ NEGATIVE ☐ POSITIVE for: ____________________________

☐ DILUTE ☐ REFUSAL TO TEST because - check reason(s) below: ____________________________

☐ ADULTERATED (adulterant/reason): ____________________________

☐ SUBSTITUTED ____________________________

☐ OTHER: ____________________________

REMARKS:

X__________________________________________

Signature of Medical Review Officer ____________________________

(PRINT) Medical Review Officer’s Name (First, M, Last) ____________________________

Date (Mo/Day/Yr) ____________________________

STEP 7: COMPLETED BY MEDICAL REVIEW OFFICER - SPLIT SPECIMEN

In accordance with applicable Federal requirements, my verification for the split specimen (if tested) is:

☐ RECONFIRMED for: ____________________________ ☐ TEST CANCELLED

☐ FAILED TO RECONFIRM for: ____________________________

REMARKS:

X__________________________________________

Signature of Medical Review Officer ____________________________

(PRINT) Medical Review Officer’s Name (First, M, Last) ____________________________

Date (Mo/Day/Yr) ____________________________

COPY 4 - EMPLOYER COPY
FEDERAL DRUG TESTING CUSTODY AND CONTROL FORM

SPECIMEN ID NO. 0000001

STEP 1: COMPLETED BY COLLECTOR OR EMPLOYER REPRESENTATIVE
A. Employer Name, Address, I.D. No.  
B. MRO Name, Address, Phone No. and Fax No.

C. Donor SSN or Employee I.D. No.
D. Specify Testing Authority: [ ] HHS [ ] NRC [ ] DOT – Specify DOT Agency: [ ] FMCSA [ ] FAA [ ] FRA [ ] FTA [ ] PHMSA [ ] USCG

E. Reason for Test: [ ] Pre-employment [ ] Random [ ] Reasonable Suspicion/Cause [ ] Post Accident [ ] Return to Duty [ ] Follow-up [ ] Other (specify)

F. Drug Tests to be Performed: [ ] THC, COC, PCP, OPI, AMP [ ] THC & COC Only [ ] Other (specify)

G. Collection Site Address: 
Collector Phone No.: 
Collector Fax No.: 

STEP 2: COMPLETED BY COLLECTOR (make remarks when appropriate) Collector reads specimen temperature within 4 minutes.

Temperature between 90° and 96° F: [ ] Yes [ ] No, Enter Remark

Collector: [ ] Split [ ] Single [ ] None Provided, Enter Remark: [ ] Observed, Enter Remark

REMARKS:

STEP 3: Collector affixes bottle(s) to bottle(s). Collector dates seal(s). Donor initials seal(s). Donor completes STEP 5 on Copy 2 (MRO Copy)

STEP 4: CHAIN OF CUSTODY - INITIATED BY COLLECTOR AND COMPLETED BY TEST FACILITY

I certify that the specimen given to me by the donor identified in the certification section on Copy 2 of this form was collected, labeled, sealed and released to the Delivery Service noted in accordance with applicable Federal requirements.

Signature of Collector

AM

SPECIMEN BOTTLE(S) RELEASED TO:

REMARKS:

STEP 5: COMPLETED BY DONOR

I certify that I provided my urine specimen to the collector; that I have not adulterated it in any manner; each specimen bottle used was sealed with a tamper-evident seal in my presence; and that the information provided on this form and on the label affixed to each specimen bottle is correct.

Signature of Donor

Daytime Phone No. ( )
Evening Phone No. ( )
Date (MM/DD/YY)

After the Medical Review Officer receives the test results for the specimen identified by this form, he/she may contact you to ask about prescriptions and over-the-counter medications you may have taken. Therefore, you may want to make a list of those medications for your own records. THIS LIST IS NOT NECESSARY. If you choose to make a list, do so either on a separate piece of paper or on the back of your copy (Copy 5). – DO NOT PROVIDE THIS INFORMATION ON THE BACK OF ANY OTHER COPY OF THE FORM. TAKE COPY 5 WITH YOU.

STEP 6: COMPLETED BY MEDICAL REVIEW OFFICER - PRIMARY SPECIMEN

In accordance with applicable Federal requirements, my verification is:

[ ] NEGATIVE [ ] POSITIVE for: 
[ ] DILUTE

[ ] REFUSAL TO TEST because – check reason(s) below:

[ ] ADULTERATED (adulterant/reason): 
[ ] SUBSTITUTED

[ ] OTHER: 

REMARKS:

Signature of Medical Review Officer

STEP 7: COMPLETED BY MEDICAL REVIEW OFFICER - SPLIT SPECIMEN

In accordance with applicable Federal requirements, my verification for the split specimen (if tested) is:

[ ] RECONFIRMED for: 
[ ] TEST CANCELLED

[ ] FAILED TO RECONFIRM for: 

REMARKS:

Signature of Medical Review Officer

COPY 5 - DONOR COPY
Instructions for Completing the Federal Drug Testing Custody and Control Form for Urine Specimen Collection

When Making Entries on a Paper CCF, use Black or Blue Ink pen and Press Firmly

Collector ensures that the name and address of the HHS-certified Instrumented Initial Test Facility (IITF) or HHS-certified laboratory are on the top of the Federal CCF and the Specimen Identification (I.D.) number on the top of the Federal CCF matches the Specimen I.D. number on the labels/seals.

STEP 1:

- Collector observes and enters remarks in STEP 2.
- Collector takes action as required.
- Collector takes action as required.

STEP 2:

- Collector checks specimen temperature within 4 minutes after receiving the specimen from Donor, and marks the appropriate temperature box in STEP 2. If the temperature is outside the acceptable range, Collector enters a remark in STEP 2 and takes action as required.
- Collector inspects the specimen and notes any unusual findings in the remarks line in STEP 2 and takes action as required.
- Collector determines the volume of specimen in the collection container. If the volume is acceptable, Collector takes action as required, and enters remarks in STEP 2.
- Collector checks the Split or Single specimen collection box. If the collection is observed, Collector checks the Observed box and enters a remark in STEP 2.

STEP 3:

- Donor watches Collector pour the specimen from the collection container into the specimen bottle(s), place the cap(s) on the specimen bottle(s), and affix the label(s)/seal(s) on the specimen bottle(s).
- Collector dates the specimen bottle label(s) after placement on the specimen bottle(s).
- Donor initials the specimen bottle label(s) after placement on the specimen bottle(s).
- Collector instructs the Donor to read and complete the certification statement in STEP 5 on Copy 2 (signature, printed name, date, phone numbers, and date of birth). If Donor refuses to sign the certification statement, Collector enters a remark in STEP 2 on Copy 1.

STEP 4:

- Collector completes STEP 4 on Copy 1 (signature, printed name, date, time of collection, and name of delivery service) and places the sealed specimen bottle(s) in a leak-proof plastic bag.
- Collector places Copy 1 in the leak-proof plastic bag. Electronic CCF: Collector places printed copy of Copy 1 in the leak-proof plastic bag and places the package label (with Specimen I.D., test facility name and contact information, and collection site name and contact information) on the outside of the bag.
- Collector seals the bag, prepares the specimen package for shipment, and distributes the remaining CCF copies as required.

Privacy Act Statement: (For Federal Employees Only)

Submission of the information on the Federal Drug Testing Custody and Control Form is voluntary. However, incomplete submission of the information, refusal to provide a specimen, or substitution or adulteration of a specimen may result in delay or denial of your application for employment/appointment or may result in removal from the federal service or other disciplinary action.

The authority for obtaining the specimen and identifying information contained herein is Executive Order 12564 ("Drug-Free Federal Workplace"), 5 U.S.C. 3301 (2), 5 U.S.C. 7301, and Section 503 of Public Law 100–71, 5 U.S.C. 7301 note. Under provisions of Executive Order 12564 and 5 U.S.C. 7301, test results may only be disclosed to agency officials on a need-to-know basis. This may include the agency Medical Review Officer (MRO), the administrator of the Employee Assistance Program, and a supervisor with authority to take adverse personnel action. This information may also be disclosed to a court where necessary to defend against a challenge to an adverse personnel action.

Submission of your SSN is not required by law and is voluntary. Your refusal to furnish your number will not result in the denial of any right, benefit, or privilege provided by law. Your SSN is solicited, pursuant to Executive Order 9397, for purposes of associating information in agency files relating to you and for purposes of identifying the specimen provided for testing for the presence of illegal drugs. If you refuse to indicate your SSN, a substitute number or other identifier will be assigned, as required, to process the specimen.

Public Burden Statement

Public Burden Statement: An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. The OMB control number for this project is 0930–0158. Public reporting burden for this collection of information is estimated to average: 5 minutes/donor; 4 minutes/collection; 3 minutes/test facility; and 3 minutes/ Medical Review Officer. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to SAMHSA Reports Clearance Officer, 1 Choke Cherry Road, Room 2–1057, Rockville, Maryland, 20857.

The number of respondents has been reduced from 7.1 to a total of 6.1 million; which reduces the total burden hours of – 240,480.

Prior to an inspection, each test facility is required to submit specific information regarding its procedures. Collecting this information prior to an inspection allows the inspectors to thoroughly review and understand the testing procedures before arriving at the test facility.

The NLCP application form has not been revised compared to the previous form.

The annual total burden estimates for the Federal Drug Testing Custody and Control Form, the NLCP application, the NLCP inspection checklist, and NLCP
SUMMARY:

The Substance Abuse and Mental Health Services Administration (SAMHSA), an operating division of the U.S. Department of Health and Human Services, is announcing a new opportunity for individuals and organizations to help solve a critical problem in today’s health environment. Specifically, there are high levels of involuntary breaks in health insurance coverage among the non-elderly population in the United States. These breaks are referred to as “churning”—when people transition from one source of insurance coverage to another when eligibility for assistance changes. Churning makes programs more complicated and costly to administer and can interrupt continuity of care, create gaps in coverage, reduce health plans’ incentive to invest in their members’ long-term wellness, and interfere with the accurate and comprehensive measurement of health care quality.

According to a study by the Urban Institute, a total of 29.4 million people will have their eligibility status change each year beginning in 2014. This challenge aligns with SAMHSA’s mission to reduce the impact of mental and substance use disorders on America’s communities. SAMHSA recognizes that enrollment in health insurance plays a significant role in fulfilling this mission, from preventive health care to behavioral health treatment and recovery. The National Survey on Drug Use and Health estimates that of the individuals currently uninsured and expected to be covered under the Affordable Care Act, 11 million will have a behavioral health need. The literature on the causes of breaks in coverage (i.e., income, housing volatility), and the high prevalence of behavioral health conditions among the uninsured, points to an interrelationship between behavioral health symptoms and difficulties complying with administrative requirements in applying for and maintaining continuous coverage. Additionally, churning has a significant amount of administrative as well as health costs, and there is a disproportionate impact of this problem among individuals with behavioral health disorders. Therefore, SAMHSA is announcing two challenge projects to help develop innovative solutions to the barriers to developing a communications strategy targeting individuals who experience churn.

The statutory authority for this challenge competition is section 105 of the America Creating Opportunities to Meaningfully Promote Excellence in Technology, Education, and Science Reauthorization Act of 2010 (COMPETES Act).

DATES: Challenge submissions accepted until August 31, 2013.

FOR FURTHER INFORMATION CONTACT:
Kevin J. Malone, 1 Choke Cherry Road, Room 8–1014, Rockville, MD 20857, Office: 240.276.2239, Email: kevin.malone@samhsa.hhs.gov.

SUPPLEMENTARY INFORMATION:

Subject of Challenge Competitions

SAMHSA is interested in identifying individuals from a marketing perspective who experience churn, and in developing innovative strategies for targeting them. SAMHSA has access to relatively good data on the individuals who are covered by Medicaid, based on disability, and the providers and community-based organizations that serve them. However, SAMHSA has very little capacity to identify the individuals among the uninsured who were disenrolled but remain eligible.

SAMHSA’s strategy is to use the following two challenges to strengthen communication with individuals in both phases of the process (prior to losing coverage, and once an individual has been disenrolled), thereby reducing incidences of churn and minimizing the period between coverage if it does happen.

1. The “Stay Covered Challenge” calls for the development of a marketing/outreach campaign designed for use by